Prognostic value of the hematogram in head and neck squamous cell carcinoma, sinonasal carcinoma and cervical sqCUP syndrome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037973

Enrollment

150

Registered

2025-09-30

Start date

2025-10-01

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICD-10-GM-codes: C32.0-C32.9, C09.0-C09.9, C10.0-C10.9, C01, C12, C13.0-C13.9, C05.0-C05.9, C06.0-C06.9, C04.0-C04.9, C03.0-C03.9, C02.0-C02.9, C00.3-C00.5, C14.0, C14.8, C30.0, C31.0-C31.9, C80.0 C32.0

Interventions

Group 1: 1. Collection of complete and differential blood count and body mass index before definitive treatment (one- time blood sample) 2. Observation within the framework of regular oncological fol

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - complete diagnostics (clinical examination, blood work, imaging, histology) - laryngeal, pharyngeal and oral cancer: histological confirmation of squamous cell carcinoma - sinonasal tumor: histological confirmation of carcinoma - CUP syndrome: malignant neoplasm of cervical lymph nodes, histological confirmation of squamous cell carcinoma, primary is unknown after complete diagnostics and therapy - follow up period > 12 months

Exclusion criteria

Exclusion criteria: -histological entities: sarcoma, lymphoma, melanoma, carcinoma of keratinized skin, mixed tumors containing other entities - concurrent active malignoma - residual or recurrent disease - secondary tumors of head and neck - systemic autoimmune disorders and chronic inflammatory diseases - immunosuppressive medication or systemic cortisone therapy (> 3 doses) in the last three months - pre-existing conditions: hematological diseases, thrombotic microangiopathy, blood count alterations caused by medication or noxae - sepsis and/ or shock - distant metastasis - therapeutic goal is palliative - follow up period < 12 months - pregnancy or lactation period at the time of initial blood work, before or during therapy

Design outcomes

Primary

Measure	Time frame
1. Overall survival: time span between initial diagnosis and death 2. Progression free survival: time span between initial diagnosis and identification of residual or recurrent disease, locoregional or distant metastasis or death Observation period: 24 months from initial diagnosis The data is collected while performing the regular oncological follow ups (clinical examination, ultrasounds, imaging techniques, endoscopy and biopsy).	—

Measure

Time frame

1. Overall survival: time span between initial diagnosis and death 2. Progression free survival: time span between initial diagnosis and identification of residual or recurrent disease, locoregional or distant metastasis or death Observation period: 24 months from initial diagnosis The data is collected while performing the regular oncological follow ups (clinical examination, ultrasounds, imaging techniques, endoscopy and biopsy).

—

Countries

Germany

Contacts

Public ContactJasmin Harmeier

Klinikum Oldenburg

harmeier.jasmin@klinikum-oldenburg.de0049 441 403 77244

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026